T/B Ratios from PET Scans and Estimated 18F−/18F-FDG Measurements
| Value | Lesion | 18F−/18F-FDG | 18F-FDG | 18F-NaF | Estimated 18F−/18F-FDG | P |
| T/B ratio by SUVmean | All lesions* | 3.3 ± 2.2 | 1.2 ± 1.1 | 9.3 ± 9.7 | 2.8 ± 1.7 | <0.001 |
| Extraskeletal lesions | 2.1 ± 1.8 | 2.1 ± 1.8 | 0.9 ± 0.4 | 1.9 ± 1.2 | 0.21 | |
| Skeletal lesions | 3.6 ± 2.2 | 1.0 ± 0.8 | 11.7 ± 9.7 | 3.0 ± 1.8 | 0.006 | |
| Skeletal lesions, prostatecancer patient | 3.3 ± 2.0 | 0.9 ± 0.9 | 9.4 ± 6.7 | 2.7 ± 1.5 | <0.001 | |
| Skeletal lesions, non–prostate cancer patient | 4.4 ± 2.3 | 1.2 ± 0.6 | 17.6 ± 13.2 | 4.0 ± 2.2 | <0.005 | |
| Osteolytic lesions | 4.6 ± 1.7 | 1.7 ± 0.6 | 13.9 ± 6.6 | 4.3 ± 2.0 | 0.28 | |
| Osteoblastic lesions | 3.4 ± 2.2 | 0.9 ± 0.8 | 11.4 ± 10.1 | 2.8 ± 1.7 | <0.001 | |
| T/B ratio by SUVmax | All lesions* | 4.8 ± 3.6 | 1.7 ± 1.7 | 14.6 ± 14.0 | 4.3 ± 3.0 | <0.007 |
| Extraskeletal lesions | 3.3 ± 4.2 | 3.1 ± 2.4 | 1.4 ± 1.1 | 2.5 ± 1.9 | 0.09 | |
| Skeletal lesions | 5.2 ± 3.3 | 1.2 ± 1.2 | 18.3 ± 13.7 | 4.8 ± 3.1 | <0.03 | |
| Skeletal lesions, prostate cancer patient | 4.7 ± 3.1 | 1.1 ± 1.2 | 16.0 ± 12.2 | 4.6 ± 3.1 | 0.61 | |
| Skeletal lesions, non–prostate cancer patient | 6.2 ± 3.6 | 1.6 ± 1.1 | 24.2 ± 15.7 | 5.1 ± 3.1 | <0.003 | |
| Osteolytic lesions | 6.5 ± 3.0 | 2.4 ± 1.2 | 22.9 ± 9.8 | 6.4 ± 3.3 | 0.62 | |
| Osteoblastic lesions | 5.0 ± 3.3 | 1.1 ± 1.1 | 17.6 ± 14.2 | 4.5 ± 3.0 | 0.011 |
↵* All lesions: both soft-tissue lesions and bone lesions.